.png){kind=icon}
.png){kind=icon}
Return
Pharmacological treatment of late-life major depressive disorder – Results from the AMSP drug surveillance program from 2007 to 2023
.png){kind=icon}
OA
AI
M
S
S
J
DOI：10.1016/j.jad.2026.122322.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
• Late-life depression shows distinct real-world psychopharmacological treatment patterns. • Older inpatients receive more antipsychotics, sedatives, and complex polypharmacy. • Antidepressant subclass use differs by age, with greater SNRI and NaSSA use in LLD. • Psychotropic polypharmacy is substantially more prevalent in older depressed patients.
Keywords:
ADR
Adverse drug reaction
AED
Antiepileptic drug
AGS
American Geriatrics Society
AMSP
Arzneimittelsicherheit in der Psychiatrie
APD
Antipsychotic drug
ADD
Antidepressant drug
CI
Confidence interval
ECT
Electroconvulsive therapy
FGA
First-generation antipsychotic
HYPD
Hypnotic drug (e.g., Z-drugs)
ICD-10
International Classification of Diseases, 10th Revision
LLD
Late-life depression
MDD
Major depressive disorder
NaSSA
Noradrenergic and specific serotonergic antidepressant
RCT
Randomized controlled trial
RR
Relative risk
RRR
Relative risk ratio
SNRI
Serotonin–noradrenaline reuptake inhibitor
SSRI
Selective serotonin reuptake inhibitor
SGA
Second-generation antipsychotic
TCA
Tricyclic antidepressant
TRD
Tranquilizing drug
Major depressive disorder
Pharmacovigilance
Drug utilization
Real-world evidence
Psychopharmacology
Drug-related side effects and adverse reactions
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
4.9
Papers:
2.1W
Citations:
6.9W
Organization
Cited Papers